US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Inc (PMN) ニュース

PMN

ProMIS Neurosciences (PMN)

ProMIS Neurosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PMN

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	05 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/05/15	05 : 01	GlobeNewswire Inc.	ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/04/30	20 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/04/09	20 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/04/04	20 : 00	GlobeNewswire Inc.	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/04/02	05 : 15	GlobeNewswire Inc.	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/03/11	20 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/02/22	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/01/22	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/01/08	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Issues Letter to Shareholders	NASDAQ:PMN	ProMIS Neurosciences Inc
2024/01/03	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences, Inc. Announces Leadership Transition	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/12/20	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Announces Publication on Novel Target for ALS	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/11/20	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/11/15	06 : 30	GlobeNewswire Inc.	ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/09/08	20 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Closes $20.4 Million Private Placement Financing	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/09/07	01 : 18	GlobeNewswire Inc.	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/08/22	05 : 12	GlobeNewswire Inc.	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/08/15	06 : 33	GlobeNewswire Inc.	ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/07/17	20 : 00	GlobeNewswire Inc.	ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/07/14	20 : 45	GlobeNewswire Inc.	ProMIS Announces Completion of Continuance	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/07/10	20 : 55	GlobeNewswire Inc.	ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/06/30	21 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/06/29	21 : 00	GlobeNewswire Inc.	CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/05/16	06 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/05/08	22 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/04/26	06 : 00	GlobeNewswire Inc.	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/04/24	20 : 30	GlobeNewswire Inc.	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/04/10	20 : 30	GlobeNewswire Inc.	ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/03/29	21 : 30	GlobeNewswire Inc.	Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023	NASDAQ:PMN	ProMIS Neurosciences Inc
2023/03/13	22 : 00	GlobeNewswire Inc.	ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting	NASDAQ:PMN	ProMIS Neurosciences Inc

Showing the most relevant articles for your search:NASDAQ:PMN

Financial Select Sector

BNP Paribas (QX)

Energy Select Sector SPDR

US Dollar vs Sterling

American Express

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約